[Longterm therapy of angina pectoris patients with a new beta-receptor blocker (author's transl)].
The beta-receptor blocker Timolol was investigated for 28 weeks in a double blind trial and then for up to 100 weeks in an open trial in patients with angina pectoris. In both phases of the investigation. Timolol caused a quite marked regression in the frequency of attacks and in the pulse rate at rest. The evaluation of therapeutic success by doctor and patient was positive for Timolol.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011412:Propanolamines / Q000627:therapeutic use*; D011674:Pulse / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D010919:Placebos; D011412:Propanolamines
Langzeitbehandlung von Angina-pectoris-Patienten mit einem neuen Betablocker